Rejuvenate Bio Secures $6 Million in Latest Funding Round

Rejuvenate Bio secured $6 million in its latest funding round, adding another data point to the Healthcare & Life Sciences funding market.

Rejuvenate Bio Raises $6 million in Funding

Rejuvenate Bio is a Digital Health company focused on the financing, <strong>Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Rejuvenate Bio operates in Healthcare & Life Sciences. Rejuvenate Bio's Unknown round shows investors are still backing digital health platforms with real scale narratives. At $6M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

the financing, <strong>Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program

Looking Ahead

Rejuvenate Bio secures funding and Merck partnership

Source reference: original announcement/article.